> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-157/
- Published: 2017-11-19T12:00:00.000Z
- Updated: 2026-09-14T23:02:34.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140168

[**Guide on Cell/Tissue-Based Product Regulatory Considerations**](https://www.fdaweb.com/guide-on-cell-tissue-based-product-regulatory-considerations/)  
*Federal Register* notice: FDA releases a guidance on “Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Minimal Manipulation and Homologous Use.” 11/17/2017

[**Expedited Programs for Regenerative Medicines Draft Guidance**](https://www.fdaweb.com/expedited-programs-for-regenerative-medicines-draft-guidance/)  
*Federal Register* notice: FDA makes available a draft guidance on “Expedited Programs for Regenerative Medicine Therapies for Serious Conditions.” 11/17/2017

[**Bone Drugs Panel to Review Lipocine Testosterone NDA**](https://www.fdaweb.com/bone-drugs-panel-to-review-lipocine-testosterone-nda/)  
*Federal Register* notice: FDA announces a 1/10/2018 Bone, Reproductive and Urologic Drugs Advisory Committee meeting that will discuss a Lipocine Inc. NDA for oral testosterone undecanoate capsules. 11/16/2017

[**Final Decision on Mepergan Fortis sNDA Administrative Review**](https://www.fdaweb.com/final-decision-on-mepergan-fortis-snda-administrative-review/)  
*Federal Register* notice: FDA announces that an initial decision of the administrative law judge (ALJ) is now the final agency decision on refusing approval of a supplemental NDA for Mepergan Fortis capsules (meperidine HCl, promethazine HCl). 11/16/2017

[**Draft Guide on GRAS Panel Best Practices**](https://www.fdaweb.com/draft-guide-on-gras-panel-best-practices/)  
*Federal Register* notice: FDA makes available a draft guidance on “Best Practices for Convening a GRAS Panel.” 11/16/2017

[**Draft Guide on Biosimilar User Fees**](https://www.fdaweb.com/draft-guide-on-biosimilar-user-fees/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Assessing User Fees Under the Biosimilar User Fee Amendments of 2017.” 11/16/2017